Treatment for High Triglycerides

Treatment Algorithm Based on Triglyceride Severity

The treatment approach for hypertriglyceridemia is determined by the severity of triglyceride elevation, with severe hypertriglyceridemia (≥500 mg/dL) requiring immediate fibrate therapy to prevent acute pancreatitis, while moderate elevations (200-499 mg/dL) are managed with statins if cardiovascular risk is elevated, and mild elevations (150-199 mg/dL) warrant lifestyle modifications with consideration of statin therapy based on 10-year ASCVD risk. 1, 2

Classification and Treatment Urgency

Hypertriglyceridemia severity determines treatment urgency 2:

Normal: <150 mg/dL 1
Mild: 150-199 mg/dL 1
Moderate: 200-499 mg/dL 1
Severe: 500-999 mg/dL 1
Very severe: ≥1,000 mg/dL 1

Initial Assessment Before Treatment

Before initiating any therapy, evaluate for secondary causes that may be driving triglyceride elevation 1:

Excessive alcohol intake - even 1 ounce per day increases triglycerides by 5-10%, and alcohol can precipitate hypertriglyceridemic pancreatitis 1
Uncontrolled diabetes mellitus - poor glycemic control is often the primary driver of severe hypertriglyceridemia and optimizing glucose control can dramatically reduce triglycerides independent of lipid medications 1
Hypothyroidism 1
Renal disease or nephrotic syndrome 1
Chronic liver disease 1
Medications: estrogen therapy, thiazide diuretics, beta-blockers, corticosteroids, antiretrovirals, antipsychotics 1, 3

Lifestyle Interventions (Foundation for All Patients)

Weight Loss

Target 5-10% body weight reduction, which produces a 20% decrease in triglycerides and is the single most effective lifestyle intervention 1, 2
In some patients, weight loss can reduce triglyceride levels by up to 50-70% 1

Physical Activity

Engage in ≥150 minutes/week of moderate-intensity aerobic activity (or 75 minutes/week vigorous activity), which reduces triglycerides by approximately 11% 1, 2

Dietary Modifications by Severity Level

For mild to moderate hypertriglyceridemia (150-499 mg/dL): 1, 2

Restrict added sugars to <6% of total daily calories 1
Limit total fat to 30-35% of total daily calories 1
Restrict saturated fats to <7% of total calories 1
Eliminate trans fats completely 2

For severe hypertriglyceridemia (500-999 mg/dL): 1

Restrict dietary fat to 20-25% of total calories 1
Eliminate added sugars completely 1

For very severe hypertriglyceridemia (≥1,000 mg/dL): 1

Implement a very low-fat diet (10-15% of total calories) 1
In some cases, consider extreme dietary fat restriction (<5% of total calories) until triglyceride levels are ≤1,000 mg/dL 1

Alcohol

Limit or completely avoid alcohol consumption for mild to moderate hypertriglyceridemia 1
Complete abstinence from alcohol is mandatory for patients with severe hypertriglyceridemia (≥500 mg/dL) to prevent hypertriglyceridemic pancreatitis 1

Pharmacologic Therapy Algorithm

For Severe to Very Severe Hypertriglyceridemia (≥500 mg/dL)

Initiate fenofibrate 54-160 mg daily immediately as first-line therapy to prevent acute pancreatitis, before addressing LDL cholesterol. 1, 2, 3

Fenofibrate reduces triglycerides by 30-50% 1, 3
The primary goal is to reduce triglycerides below 500 mg/dL to prevent pancreatitis 1
Do not start with statin monotherapy when triglycerides are ≥500 mg/dL, as statins provide only 10-30% triglyceride reduction and are insufficient for preventing pancreatitis at this level 1
Once triglycerides are reduced below 500 mg/dL with fenofibrate, initiate or optimize statin therapy to address LDL-C and cardiovascular risk 1

Dosing considerations for fenofibrate: 3

Initial dose for severe hypertriglyceridemia: 54 mg to 160 mg per day 3
Maximum dose: 160 mg once daily 3
Must be given with meals to optimize bioavailability 3
In patients with mild to moderately impaired renal function, initiate at 54 mg per day and increase only after evaluation of effects on renal function and lipid levels 3
Avoid in patients with severe renal impairment 3

For Moderate Hypertriglyceridemia (200-499 mg/dL)

Initiate or intensify statin therapy if LDL-C is elevated or 10-year ASCVD risk is ≥7.5%. 1, 2

Statins provide a 10-30% dose-dependent reduction in triglycerides 1
Target non-HDL-C <130 mg/dL 1
If triglycerides remain >200 mg/dL after 3 months of optimized lifestyle modifications and maximally tolerated statin therapy, consider adding prescription omega-3 fatty acids (icosapent ethyl 2-4g/day) 1, 2

For Mild Hypertriglyceridemia (150-199 mg/dL)

Consider initiating moderate-intensity statin therapy for patients with 10-year ASCVD risk ≥7.5% or persistently elevated nonfasting triglycerides ≥175 mg/dL. 1, 2

Prescription Omega-3 Fatty Acids (Icosapent Ethyl)

Icosapent ethyl is specifically indicated as adjunct to maximally tolerated statin therapy for patients with triglycerides ≥150 mg/dL and established cardiovascular disease OR diabetes with ≥2 additional risk factors. 1, 2

Dose: 2-4 g/day 1, 2
Provides 25% reduction in major adverse cardiovascular events based on the REDUCE-IT trial 2
Can be added if triglycerides remain elevated after fenofibrate and lifestyle optimization 1
Monitor for increased risk of atrial fibrillation with prescription omega-3 fatty acids 1, 2
Over-the-counter fish oil supplements are not equivalent to prescription formulations and should not be substituted 1

Combination Therapy Considerations

Fibrate + Statin Combination

When combining fenofibrate with statins, use lower statin doses to minimize myopathy risk, particularly in patients >65 years or with renal disease. 1, 2

Fenofibrate has a better safety profile than gemfibrozil when combined with statins 1
Monitor creatine kinase levels and muscle symptoms 1
The combination of high-dose statin plus fibrate increases myopathy risk 1

Special Populations and Considerations

Diabetic Patients

Aggressively optimize glycemic control in diabetic patients with very high triglycerides and poor control, as this may obviate the need for additional lipid medications. 1

Poor glycemic control is often the primary driver of severe hypertriglyceridemia 1
Improving glycemic control can dramatically reduce triglycerides independent of lipid-lowering medications 1

Monitoring and Follow-up

Reassess fasting lipid panel in 6-12 weeks after implementing lifestyle modifications 1
Monitor lipid levels at 4-8 week intervals after initiating or adjusting fenofibrate 1
Once goals are achieved, follow-up every 6-12 months 1
Consider reducing the dosage of fenofibrate if lipid levels fall significantly below the targeted range 3
Withdraw therapy in patients who do not have an adequate response after two months of treatment with the maximum recommended dose of 160 mg once daily 3

Critical Pitfalls to Avoid

Do not delay fibrate initiation while attempting lifestyle modifications alone in patients with triglyceride levels ≥500 mg/dL, as pharmacologic therapy is mandatory to prevent pancreatitis 1
Do not start with statin monotherapy when triglycerides are ≥500 mg/dL 1
Do not overlook the importance of glycemic control in diabetic patients, as this can be more effective than additional medications in some cases 1
Avoid bile acid sequestrants when triglycerides are >200 mg/dL, as they are relatively contraindicated 1
Do not use fenofibrate in patients with severe renal impairment, active liver disease, preexisting gallbladder disease, or nursing mothers 3

What is the treatment for hypertriglyceridemia?

Help us tailor your experience